1026134-63-3
1026134-63-3
Chemical Structure
Nelonicline
Synonym(s): ABT-126
- CAS No.: 1026134-63-3
- Formula:C17H19N3OS
- Molecular Weight:313.42
IUPAC Name: 2-(((1r,3R,4s,5S,7s)-1-azaadamantan-4-yl)oxy)-5-phenyl-1,3,4-thiadiazole
InChIKey: QZDCYUCETTWCMO-WTGKZIDZSA-N
SMILES: [C@@H]1([C@H]2C[C@H](C3)C[C@@H]1C[N@]3C2)OC4=NN=C(C5=CC=CC=C5)S4
Biological Activity: Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (Ki=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nelonicline | 99.82% | Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (Ki=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.75
HY-16748ANelonicline citrate -
Similarity Score 0.44
HY-108038ABT-107 -
Similarity Score 0.43
HY-185056Ferfluor-1 -
Similarity Score 0.43
HY-123565TP-S1-68 -
Similarity Score 0.42
HY-W0751962,5-Di(pyridin-3-yl)-1,3,4-thiadiazole -
Similarity Score 0.42
HY-22183Anticonvulsant agent 3 -
Similarity Score 0.41
HY-129708LU 2443 -
Similarity Score 0.41
HY-118795SC-22716 -
Similarity Score 0.40
HY-W0751982,5-Di(pyridin-4-yl)-1,3,4-thiadiazole -
Explore the MedChemAI to find more analogs
References
- [1]. Zhang D, et al. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord. 2015;30(14):1901-1911. [Content Brief]
- [2]. Haig G, et al. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study. Neuropsychopharmacology. 2016;41(12):2893-2902. [Content Brief]
- [3]. Gault LM, et al. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimers Res Ther. 2016;8(1):44. Published 2016 Oct 18. [Content Brief]
